Other News To Note
Wednesday, October 31, 2012
Complix NV, of Hasselt, Belgium, was awarded a grant of €1.9 million (US$2.4 million) from the Flanders government through the Agency for Innovation by Science and Technology in Flanders to speed up development of its cell penetrating alphabodies (CPABs) for a number of disease targets, including cancer.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.